Mike Mahoney: Sure. On WATCHMAN, we had a terrific year in ’22. As I said, maintaining, call it, 90% share, potentially slightly above that, grew 24% for the full year. It’s a very healthy market, so call it, 25% growth we expect in ’23, two companies in the marketplace today. Similar to previous comments, the success of WATCHMAN is really manyfold. The safety, consistency and proven effectiveness through clinical trial in everyday practice at WATCHMAN, physicians are extremely comfortable in using the device. They’re very comfortable with the support team they have from Boston in the lab with them and the referring physician community is seeing such strong benefits from the LAs procedure that is helping to drive that market growth.
So it’s an excellent market. It’s also a product that’s — a procedure that’s profitable for hospitals. And the procedure time today continues to improve, which is really important for hospitals. So the overall market context is very good. We have the leading platform, and we have a new product, new steerable sheath coming this year and the next-gen WATCHMAN platform coming about a year from now. So we have a differentiated pipeline as well. Neo2 is doing extremely well in Europe. We just launched — or just having some implementation of our XL valves. That’s part of the U.S. trial. There was, I think, some — a bit of inaccurate reporting on that one. We do not expect that XL to slow down the approval process for the U.S. So that does not have an impact on U.S. approval.
And that XL valve is important because it’s about a one-third of the procedures are using that size valve in Europe. So we’re doing quite well, growing faster than market in Europe without that, and eventually, we’ll be adding that to approval. So we’re excited about that. ACURATE neo2, we expect it to be approved in 2024 in the U.S.
Cecilia Furlong: Great. Thank you for taking the question.
Operator: And the next question, currently, I have is Josh Jennings with Cowen. Please go ahead.
JoshJennings: Hi, good morning. Thanks for taking the question. I was hoping to start off with just your Apollo acquisition and get you into the diabetes — sorry, not diabetes, the obesity segment. And I just wanted to hear about your outlook for that portfolio but also just device-based intervention opportunities in obesity from a higher level and whether this portfolio could become a long-term growth driver for the endoscopy franchise? And then the follow-up is just on your neuromodulation business. Congratulations on SOLIS trial results. And I think three of the big competitors in the space have a peripheral diabetic neuropathy indication now with different levels of evidence. But I was hoping you could just review Boston’s plan to generate clinical evidence for that indication going forward? Thanks a lot.
Mike Mahoney: Yes. So on Apollo Endosurgery overall, it’s really consistent with our overall strategy of category leadership, which is driving above-market growth and continuing to advance new therapies where we can be the leader. When we look at endoluminal surgery, we think that is really the next frontier for our endo business. And you see a terrific uptake of endoluminal surgery, I would say, outside the U.S., particularly in Japan, a bit more so in Europe and less so in U.S. And so we think endoluminal surgery will really continue to build momentum over the next coming years and Apollo is a platform that’s most used by physicians pick outside the U.S. to perform these procedures with a product called OverStitch and xTAC.
So we think the addition of Apollo into our current platform will obviously make us the number one strongest endoluminal surgery portfolio, but also put us in a position, as Dr. Duncan would say, to help train the field because these are procedures that require significant physician training to get great outcomes, and we’ll be able to do that with the Apollo platform.
Unidentified Company Speaker : And then on Neuromod, I asked about SOLIS.
Mike Mahoney: On SOLIS with SCS, again, we did see some improvement in that overall SCS business in the fourth quarter, growing 4% in the quarter. SOLIS, we’re pleased with the three-month results that we expected. We expect indication and approval for nonsurgical back by the year-end of 2023.
Unidentified Company Speaker : And we’re in early clinical work for PDN right now and haven’t announced any timelines, but we’ll look to invest in that space. And that concludes our call for today. So thank you for joining us. We appreciate your interest in Boston Scientific. If we were unable to get to your question or if you have any follow-ups, please don’t hesitate to reach out to the Investor Relations team. Before you disconnect, Drew will give you all of the pertinent details for the replay. Drew?
Operator: Please note a recording will be available in one hour by dialing either 1-877-344-7529 or 1-412-317-0088 using replay code 7345419 until February 8, 2023 at 11:59 p.m. Eastern Time. The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.
